CGTX

Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.

Cognition Therapeutics, Inc. (CGTX) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
D+
Factor Score 1.5 / 5.0
Momentum
D+
Factor Score 1.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.6
EV / EBITDA -0.7
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -35.6%
Price Return 12M -59.6%
Catalyst Signal 0.00
Market Cap $63.7M
TTM Revenue N/A
Price / Sales N/A
ROE -83.8%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 C+ (2.5) D+ (1.8) D+ (1.5) D+ (1.7) C+ (2.6) C- (2.0)
2026-11-04 C+ (2.5) C (2.3) D+ (1.6) D+ (1.7) C+ (2.7) C (2.2)
2026-10-28 C+ (2.5) C (2.2) D+ (1.5) C- (1.9) C+ (2.7) C (2.2)
2026-10-21 C+ (2.5) C (2.2) D+ (1.5) C- (1.9) C+ (2.6) C (2.2)
2026-10-14 C+ (2.5) C (2.2) D+ (1.5) C (2.4) C+ (2.6) C (2.3)
Page 1 of 7